Ltd.jp

Gary Stiles, MD, Executive Vice President and
Chief Medical Officer, Wyeth Pharmaceuticals.
While the NIH conference focused on menopausal symptoms, another important
health issue for women is postmenopausal bone loss -- an asymptomatic
condition that can lead to the development of osteoporosis.
Using estrogens with or without progestins may increase your chances of
getting heart attacks , strokes, breast cancer, and blood clots.

About Wyeth
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading
products in the areas of women's health care, cardiovascular disease , central
nervous system, inflammation, transplantation, hemophilia, oncology, vaccines
and nutritional products.01 to $0.

abnormal fwhc

Paul Hasting, QLT Inc. Through natural biodegradation, the active compound is
released in a slow and sustained manner over a pre-determined therapeutic
period.

PREMARIN is used after menopause to reduce moderate to severe hot flashes;
to treat moderate to severe dryness, itching , and burning, in and around the
vagina; and to help reduce your chances of getting osteoporosis (thin, weak
bones). In a clinical trial, there was no difference in the commonly
reported (greater than or equal to 5%) side effects for women taking PREMPRO
0., a privately-held company that develops and
markets innovative delivery systems for the treatment of cancer. The
ThinPrep(R) System is the most widely used method for cervical cancer
screening in the United States.
Cytyc, ThinPrep , FirstCyte, and NovaSure are registered trademarks of
Cytyc Corporation.

tampons skipped

- Biodegradable slow -release implant is a liquid delivery system
containing an active compound that is injected into the body where it forms a
small solid implant. For further
information about Sosei, please visit http: //www., started to grow into a comprehensive
company with functions of development, manufacturing , marketing and sales. Women Encouraged to Talk With Their Doctor
About an Individualized Treatment Approach

MADISON, N. Up to 20 percent
of a woman 's expected lifetime bone loss can occur in the years immediately
following menopause.
The benefits and risks of HT should be discussed between a woman and her
doctor before initiating therapy .5 mg compared to those taking placebo.
MammoSite revenue in 2004 was approximately $12.cytyc. Cytyc products cover a range of women's health
applications, including cervical cancer screening, breast cancer risk
assessment, and treatment of excessive menstrual bleeding.

menorrhagia skipping

For more information, visit the company
web site at http://www.45 mg/1. In general, the addition of a progestin is recommended for women
with a uterus. "This
acquisition enables us to expand our product offerings into cancer
treatment while leveraging our existing infrastructure and expertise
in women's health and oncology . Cytyc expects
sales related to this acquisition in the last three quarters of 2005
to be in the range of $15 million to $17 million and for the
transaction to be $0.

tampons fwhc

Nippon Organon K.
For further information please visit http://www.5 mg, and
PREMPRO 0. The Company's major divisions
include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health. MammoSite RTS dramatically
reduces treatment time to five days compared to 30-35 days for
traditional whole breast external beam radiation therapy. While there
are no specific FDA patient restrictions on the use of MammoSite,
current medical society guidelines recommend use with patients at
least 45 years old with tumors less than 3 centimeters with negative
lymph nodes.6 million,
representing 50 percent growth over the previous year.
Cytyc Corporation is a leading women's health company that
designs , develops, manufactures, and markets innovative and clinically
effective products.

abnormal dispels

They are currently marketed for the treatment of
prostate cancer by QLT, Inc's licensee, Sanofi-Aventis. Various dosages of
Eligard(R) are also marketed in Germany, Australia, Canada and some Latin
American countries as well as in the US."
Mr., A panel meeting in
conjunction with this week's Conference on the Management of Menopause-Related
Symptoms, convened by the National Institutes of Health (NIH ), has issued a
statement supporting the use of postmenopausal hormone therapy (HT) for the
management of moderate to severe menopausal symptoms, such as hot flashes,
night sweats, and vaginal dryness .3 mg, PREMARIN 0.5 mg.
PREMARIN and PREMPRO should be used at the lowest effective dose and for
the shortest duration consistent with your treatment goals and risks.3 mg/1.
PREMARIN and PREMPRO should not be used if you have unusual vaginal
bleeding, have or had cancer of the breast or uterus, had a stroke or heart
attack in the past year, have or had blood clots, have liver problems , are
allergic to any of the ingredients in PREMARIN or PREMPRO, or think you may be
pregnant.

----Cytyc
Corporation (Nasdaq: CYTC), a leading women's health company, today
announced that it has entered into a definitive agreement to acquire
Proxima Therapeutics, Inc.
transaction, fourth quarter and year-end results, business highlights
and future expectations during a conference call on February 10 at
9:00 a. (Eastern).

alana empowers

Sosei Files Marketing Authorisation Application for SOT-375

Commenting on this significant event, Sosei's CEO Shinichi Tamura stated:
"SOT-375 is the first product in our pipeline to reach the submission stage
and is a key milestone in Sosei's development as a company. One of Nippon
Organon's business strategies is to focus on the field of urology
therapeutics .K.
The NIH conference provided a forum for researchers and clinicians to
discuss the physiologic causes of menopausal symptoms and a range of treatment
interventions.
PREMPRO is used after menopause in women with a uterus to reduce moderate
to severe hot flashes; to treat moderate to severe dryness, itching, and
burning, in and around the vagina; and to help reduce your chances of getting
osteoporosis (thin, weak bones). If
using PREMARIN or PREMPRO only to treat your symptoms of vaginal dryness,
consider topical therapies first.5 mg were breast pain/enlargement, vaginitis due to yeast
or other causes, leg cramps, vaginal spotting/bleeding, and painful
menstruation."
Proxima launched the MammoSite RTS following clearance by the U.com, where the event will
be available for replay approximately two hours following the webcast
until February 25, 2005.

placebos menstruation

TOKYO, Japan and LONDON, England,
Sosei Co. Ltd.com
About QLT, Inc. QLT Inc. is listed on the Nasdaq Stock Market
under the trading symbol "QLTI" and on The Toronto Stock Exchange under the
trading symbol "QLT.
Sullivan, chairman, president, and chief executive officer. The call will be hosted by Patrick Sullivan,
chairman, president, and chief executive officer; Tim Adams, chief
financial officer; Daniel Levangie, executive vice president and chief
commercial officer; and John McDonough, senior vice president,
development and operations. The Company disclaims any
obligation to publicly update or revise any such statements to reflect
any change in Company expectations or events, conditions , or
circumstances on which any such statements may be based, or that may
affect the likelihood that actual results will differ from those set
forth in the forward-looking statements.

skipping alana

It enriches its core product
pipeline by in-licensing compounds from Western and Japanese companies, by
its distinctive Drug Reprofiling Platform(R) (DRP(R)) and through new
molecular entity (NME) research programmes in collaboration with
biopharmaceutical companies and universities both in Japan and the West. Its low dose hormone therapies are part of a family of
well-studied products, which includes multiple strengths of PREMARIN and
PREMPRO.

* Do not use estrogens with or without progestins to prevent heart
disease, heart attacks, strokes, or dementia. The
Company assumes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise.02 dilutive to earnings in 2005,
breakeven to earnings in the fourth quarter 2005, and accretive in
2006.
Cytyc management will discuss the Proxima Therapeutics, Inc. Investors are cautioned that statements in this press release
which are not strictly historical statements , including, without
limitation, statements relating to the Company's financial condition,
operating results and future economic performance, and management's
expectations regarding future growth opportunities , product acceptance
and business strategy, constitute forward-looking statements.

skipped menorrhagia

's CEO commented: "We are delighted with
Sosei's progress in filing for approval of SOT-375 in Japan.
Sosei Co.organon.co.
The panel discussed alternative therapies, such as bioidenticals and over-
the -counter remedies, currently being used as potential treatment options for
the relief of menopausal symptoms, but noted the paucity of safety and
efficacy data.
"Medicine and science continue to evolve, and Wyeth is committed to
offering menopausal women and their health care providers innovative , well-
studied products to meet individual treatment goals and risks," said Dr. 8244923). These
statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties , which could
cause actual outcomes and results to differ materially from those
statements.

menstrual dysmenorrhea

75 mg of the drug substance at a controlled rate over 30 days. Only HT has been proven both to relieve menopausal
symptoms and to prevent postmenopausal osteoporosis.45 mg/1. Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies.m. The ThinPrep System consists of the
ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, ThinPrep(R)
Imaging System, and related reagents, filters, and other supplies.
Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.

menstrual tampons

Wyeth Pharmaceuticals, a division of Wyeth
(NYSE: WYE), supports the panel's statement on the treatment of menopausal
symptoms and encourages women experiencing menopause to talk with their doctor
to determine treatment options as appropriate, based on an individual woman's
treatment goals and personal health profile.45 mg, Prempro(TM)
(conjugated estrogens/medroxyprogesterone acetate tablets) 0.

skipping irregularities

K.
About Sosei Co.K.3 mg/1.
In a clinical trial, the most commonly reported (greater than or equal to
5%) side effects that occurred more frequently with PREMARIN were vaginitis
due to yeast or other causes, vaginal bleeding, painful menstruation, and leg
cramps .
"The acquisition of Proxima is another key milestone in Cytyc's
strategic evolution and our ongoing mission to provide innovative and
effective products that improve women's lives," said Patrick J . Cytyc Surgical Products, a wholly owned
subsidiary of Cytyc Corporation, manufactures and markets the
NovaSure(R) Impedance Controlled Endometrial Ablation System, or the
NovaSure(R) System, an innovative endometrial ablation device to treat
menorrhagia, or excessive menstrual bleeding.

menstrual menstruation

The company is capitalising on its extensive global network established over
the past 10 years in its successful technology transfer business. In
April 1999, Nippon Organon K. HT should be used at the lowest effective
dose and for the shortest duration of time consistent with a woman's
individual treatment goals and risks. This transaction is expected to close by the end of
the first quarter and will be subject to customary closing conditions
and clearance under the Hart-Scott Rodino Antitrust Improvements Act. A webcast and replay of the call may be
accessed at Cytyc's website, http://ir .

menorrhagia fwhc

In January 2003 Sosei in-licensed the
exclusive rights to develop and commercialise SOT-375 in Japan from US based
QLT, Inc (formerly Atrix Laboratories, Inc). is a global biopharmaceutical company specializing in
developing treatments for cancer, eye diseases and dermatological and
urological conditions.K. Currently taken by about 4 million women in the United States alone,
these products are prescribed more often than any other brand of
postmenopausal HT.
Report any unusual vaginal bleeding right away while you are taking
these products.

The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation , risks
associated with the inherent uncertainty of the timing and success of
pharmaceutical research , product development, manufacturing,
commercialization, economic conditions including interest and currency
exchange rate fluctuations, changes in generally accepted accounting
principles, the impact of competitive or generic products, trade buying
patterns, wars or terrorist acts, product liability and other types of
lawsuits, the impact of legislation and regulatory compliance and obtaining
reimbursement, favorable drug pricing, access and other approvals,
environmental liabilities, and patent, and other risks and uncertainties,
including those detailed from time to time in the Company's periodic reports,
including current reports on Form 8-K, quarterly reports on Form 10-Q and the
annual report on Form 10-K, filed with the Securities and Exchange Commission.
Proxima 's lead product, the proprietary MammoSite(R) Radiation
Therapy System (RTS), is a single-use device for the treatment of
breast cancer that positions radiation sources directly into the
post-lumpectomy site to optimize radiation treatment delivery while
minimizing damage to healthy tissue. Risks and uncertainties include, among others, dependence
on key personnel and proprietary technology, uncertainty of product
development efforts and product acceptance, management of growth and
product diversification , risks associated with litigation and
arbitration, the effective integration of acquired businesses and
technologies, competition and competitive pricing pressures, risks
associated with the FDA regulatory approval processes and any
healthcare reimbursement policies, introduction of disruptive
technologies, as well as other risks detailed in the Company's filings
with the Securities and Exchange Commission, including under the
heading "Certain Factors Which May Affect Future Results " in its 2003
Annual Report on Form 10-K and its most recent Quarterly Report on
Form 10-Q filed with the Commission.

dysmenorrhea menorrhagia

In the US, the Eligard(R)
products contain various dosages of leuprolide acetate which have been
approved by the FDA.sosei. (Osaka)
Nippon Organon K. provides innovative products specializing in urology,
gynecology, psychiatry and anesthesia, and contributes to the health of
people and their quality of life. Estimates vary, but most women going through menopause
experience symptoms, such as hot flashes. These symptoms can have a
significant negative impact on a woman 's daily activities.

Business Editors/Health Editors

MARLBOROUGH, Mass.S.

wingfoot alana

This
formulation is administered subcutaneously where it forms a biodegradable
slow-release implant., which is
the human health care business unit of Akzo Nobel, was founded in 1960.

About the PREMARIN Family of Products
Wyeth Pharmaceuticals is the leader in women's health, with a long history
of product innovation. If you do not have symptoms, non-estrogen
treatments should be carefully considered before taking PREMARIN and PREMPRO
solely for the prevention of postmenopausal osteoporosis.

Cytyc Expands Women's Health Presence with Acquisition of Proxima Therapeutics Inc.; Cash Transaction of $160 million plus Two-Year Earnout

In addition, we will be further
strengthening our formidable sales force with the addition of
Proxima's oncology-focused sales team.

menorrhagia dispels

"
About Nippon Organon K.

amenorrhea dysmenorrhea

Hans M. (Vancouver, Canada)
QLT, Inc.qltinc. Products are available
in multiple strengths , including four low doses options: Premarin(R)
(conjugated estrogens tablets, USP) 0. Using
estrogens, with or without progestins, may increase your risk of
dementia, based on a study of women age 65 years or older. To date, more than 7,000
breast cancer patients have been treated with MammoSite. The
ThinPrep System also provides the platform from which the Company
launched its expansion into breast cancer risk assessment with the
FirstCyte(R) Breast Test.

premenstrual uterus

(4565, Tokyo Stock Exchange MOTHERS index) announced today
that a marketing authorisation application for SOT -375 (known as Eligard(R)
in the US) has been submitted to the Japanese Ministry of Health, Labour and
Welfare (MHLW) requesting approval for marketing in Japan.
Stiles.625 mg/2. The
purchase price of $160 million, plus a two-year earnout based on
incremental sales growth in breast related products will be paid out
of existing cash. International participants may
dial 719-457-0820; the pin number is the same.

tampons predicting

Sosei has a collaborative strategy
agreement with Nippon Organon K., reinforced by acquiring a part of the
pharmaceutical division of Kanebo, Ltd.
"The panel agreed that hormone therapy remains the most consistently
effective therapy for treating menopausal symptoms and is, by far, the most
intensively studied," said Dr.
Associations of women's health experts -- including the American College
of Obstetricians and Gynecologists (ACOG), the North American Menopause
Society (NAMS), the American Society for Reproductive Medicine (ASRM), and the
International Menopause Society (IMS) -- agree that postmenopausal estrogen
and estrogen plus progestin therapies are highly effective for the alleviation
of moderate to severe hot flashes, night sweats, and vaginal dryness , and are
also appropriate therapies for the prevention of postmenopausal osteoporosis
in symptomatic women.
With more than 60 years of science and clinical experience, there is an
extensive catalogue of data documenting the benefits and risks of the
PREMARIN(R) (conjugated estrogens) Family of Products . Vaginal bleeding after menopause may be a warning sign
of cancer of the uterus (womb). It is a leader in the
discovery, development, manufacturing, and marketing of pharmaceuticals,
vaccines , biotechnology products and nonprescription medicines that improve
the quality of life for people worldwide.
Actual results may vary materially from the forward-looking statements.

Forward -looking statements in this press release are made pursuant
to the provisions of Section 21E of the Securities Exchange Act of
1934. The Company cautions readers not
to place undue reliance on any such forward-looking statements, which
speak only as of the date they were made.

amenorrhea menstrual

Japan is the
second largest pharmaceutical market in the world and clearly an important
opportunity for us."
President and Representative Director of Nippon Organon, Mr. Ltd., founded in 1990 by Shinichi Tamura, the ex -CEO of
Genentech Japan, is a leading Japanese biopharmaceutical company with
significant expertise in drug development. We have combined our expertise in the discovery,
development, commercialization and manufacture of innovative drug therapies
with our unique technology platforms to create highly successful products
such as Visudyne(R) and Eligard(R).

NIH State-of-the-Science Panel Supports Use of Hormone Therapy for Treatment of Moderate to Severe Menopausal Symptoms

Food and Drug Administration in May 2002.

uterine tampons

SOT-375 is an injectable formulation of leuprolide acetate designed to
deliver 3. to co-promote the product in Japan.A.
van Eerd stated: "The filing of the marketing application for SOT-375 means
we are looking forward to the early launch of this product.com., a subsidiary of Organon International Inc.J.
In a clinical trial, the most commonly reported (greater than or equal to
5%) side effects that occurred more frequently with PREMPRO 0. A telephonic replay of the
call will be available through February 25, 2005, by calling
888-203-1112 (Replay Pin No.

dispels uterus

K.

What is the most important information you should know about PREMARIN
(estrogens) or PREMPRO (a combination of estrogens and a progestin)?

* Estrogens increase the chances of getting cancer of the uterus. Your health care provider should check
any unusual vaginal bleeding to find out the cause.5 mg and
PREMPRO 0. Cytyc believes the overall market opportunity to be in
the $300 million range.

dysmenorrhea uterine

Sosei is developing SOT-375 and has successfully
finished a series of clinical studies in Japan needed to complete the
marketing authorisation dossier. I believe that
our product will strongly benefit patients in Japan and will be a worthwhile
alternative to existing treatments. Avishot(R), one of our core products, is already used to treat
the urological complications of benign prostatic hypertrophy and our
experience with Avishot(R) will bring synergy benefits when we come to launch
SOT-375."
Notes for Editors:
- Leuprolide acetate is a luteinizing hormone-releasing hormone (LHRH)
agonist and is indicated for prostate cancer, uterine cancer, menorrhagia
(excessive menstrual bleeding) and breast cancer.
Sosei is also developing its own sales and marketing organization in Japan. You and your
health care provider should talk regularly about whether you still need
treatment with estrogens.

Those without web access may access the call
by calling 800-817-4887 or 913-981-4913.